Clinical Trial Update: A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial of danicopan for six months in participants with C3 glomerulopathy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulonephritis
• C3 Glomerulopathy
• Dense Deposit Disease

Drugs mentioned

• Danicopan (danicopan)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: C3 Glomerulopathy, C3 Glomerulonephritis | Phase 2 | Status: COMPLETED | Results posted: 2021-11-04